Instituto Europeo di Oncologia
Instituto Europeo di Oncologia
Milan, Italy5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-29 | NCT06172127 | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, squamous cell carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-20 | NCT02503423 | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-01-16 | NCT05737628 |